Aether Industries Limited (NSE: AETHER, BSE: 543534) is a Surat, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹20,419 Cr, it ranks #370 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹1,412.70 (as of 25 Oct 2026), the share price is 22.1% below its 52-week high of ₹1,814.10 and 94.1% above its 52-week low of ₹728.00. The share price is up 88.8% over one year and down 1.0% over three months.
| Current Price | ₹1,412.70 |
|---|---|
| Market Cap | ₹20,419 Cr |
| NSE Symbol | AETHER |
| BSE Code | 543534 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 92.1 |
| Return on Equity | 9.81% |
| Return on Assets | 6.36% |
| 52-Week Range | ₹728.00 – ₹1,814.10 |
| 1-Year Price Change | +88.8% |
| 3-Month Price Change | -1.0% |
| Beta (1Y) | 0.12 |
| Headquarters | Surat, Gujarat |
| Website | www.aether.co.in |
| Revenue | ₹327 Cr |
|---|---|
| Net Profit | ₹63 Cr |
| Net Margin | 19.2% |
| EPS (Basic) | ₹4.77 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aether Industries Limited produces and sells advanced intermediates and specialty chemicals in India and internationally. It also large-scale manufacturing, contract research and manufacturing services, as well as contract/exclusive manufacturing services. The company serves its products to the chemical industry, including multinational, regional, and domestic companies in the pharmaceuticals, agrochemicals, materials science, textiles, coatings, high-performance photography, additives, and oil and gas industries. It also exports its products. Aether Industries Limited was incorporated in 2013 and is headquartered in Surat, India.
1. Contract Manufacturing-This segment engages in the contract manufacturing of specialty chemicals and intermediates. 2. Contract Research and Manufacturing Services (CRAMS)-This segment provides contract research and manufacturing services. 3. Others-0 4. Large Scale Manufacturing-This segment manufactures specialty chemicals and intermediates.
1. Contract/Exclusive Manufacturing-46.3% 2. Large Scale Manufacturing-43.2% 3. CRAMS-9.2% 4. Others-1.3%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,73,448 Cr | 71.2 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹20,419 Cr | 92.1 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹16,073 Cr | 27.7 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,922 Cr | 43.2 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹3,361 Cr | -382.6 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,153 Cr | 110.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹556 Cr | 25.9 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹501 Cr | 24.8 | — | — | +39.4% |
| Infinium Pharmachem Limited | ₹475 Cr | 37.6 | — | — | +13.5% |
Listed by market capitalisation. Ratios are shown for context only.
Aether Industries Limited is trading at ₹1,412.70, with a market capitalisation of ₹20,419 Cr.
Aether Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Aether Industries Limited has a P/E of 92.1 and a return on equity of 9.81%.
Aether Industries Limited is listed on the NSE under the symbol AETHER and on the BSE under the scrip code 543534.
Aether Industries Limited's share price is up 88.8% over one year and down 1.0% over three months. Its 52-week range is ₹728.00 to ₹1,814.10.
In Q1 FY27, Aether Industries Limited reported revenue of ₹327 Cr and net profit of ₹63 Cr, with basic EPS of ₹4.77 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.